CCR8 and neoplasm: The hypothesis that therapeutic depletion of CCR8+ cells rather than blockade of CCR8 function leads to induction of anti‐tumour immunity is indeed consistent with recently reported findings that administration of anti‐CCR8 nanobodies with blocking function does not augment tumour immunity, but does so when provided the capability for ADCC [40].